Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $384000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 163.01% to $384000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 million, a 72.53% increase, with the full-year FY2024 number at $581000.0, down 6.44% from a year prior.
  • Depreciation & Amortization (CF) was $384000.0 for Q3 2025 at Vivos Therapeutics, up from $306000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $384000.0 in Q3 2025 to a low of $41000.0 in Q1 2022.
  • A 5-year average of $182645.9 and a median of $169000.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 76.84% in 2022, then surged 326.83% in 2023.
  • Vivos Therapeutics' Depreciation & Amortization (CF) stood at $168000.0 in 2021, then rose by 0.6% to $169000.0 in 2022, then decreased by 11.83% to $149000.0 in 2023, then decreased by 3.36% to $144000.0 in 2024, then surged by 166.67% to $384000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Depreciation & Amortization (CF) are $384000.0 (Q3 2025), $306000.0 (Q2 2025), and $177000.0 (Q1 2025).